HuR is a key gatekeeper of liver homeostasis and prevents hepatocellular carcinoma and non-alcoholic fatty liver disease-related fibrosis, suggesting that the HuR-dependent network could be used therapeutically. Here, ELAVL1 is linked to metabolic dysfunction-associated steatotic liver disease.